RAPID AFib Decision Aid for Stroke Prevention in Atrial Fibrillation

NCT ID: NCT05900414

Last Updated: 2025-04-02

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-01
• Study Completion Date: 2025-10-31

Brief Summary

The goal of this pilot clinical trial is to evaluate the utility of a new electronic patient decision aid for stroke prevention therapy in patients with atrial fibrillation. The main questions it aims to answer are:

Is the patient decision aid acceptable to both patients and physicians? Does the patient decision aid lead to more effective shared decision-making than standard care among patients with atrial fibrillation who are considering stroke prevention therapy? Participants with a recent diagnosis of atrial fibrillation will be enrolled before an upcoming specialist physician visit. Researchers will compare a pre-visit intervention consisting of standard educational materials plus use of the patient decision aid to educational materials alone to see if using the decision aid results in improved shared decision making during the clinic visit.

Detailed Description

Background:

Atrial fibrillation (AF) leads to a 4-fold increased risk of stroke, accounting for 15-20% of the 50,000 strokes suffered by Canadians each year. The annual stroke risk in untreated patients is 4.5%, but varies 10-fold based on risk factors captured in clinical prediction tools. Given that oral anticoagulation (OAC) reduces stroke risk by 65%, the majority of AF-associated strokes are potentially preventable. All current Canadian and international AF guidelines strongly recommend use of clinical prediction rules to assess stroke risk, and anticoagulation of high-risk patients. However, population-based studies continue to document significant rates of risk-discordant stroke prevention therapy. Addressing this care gap is a major knowledge translation challenge.

Patient decision aids are knowledge translation tools that can facilitate a process of shared decision-making to improve patient knowledge and decision quality. These tools have the potential to improve both initial therapy selection and adherence, ultimately reducing the risks of AF-associated stroke and unnecessary bleeding. We have developed and performed initial user testing for a new, web-based decision aid, called Risk Assessment and Personal preferences to Improve Decisions for Atrial Fibrillation (RAPID AFib). The tool has 3 sequential functions: (1) it estimates an individual's risk for stroke and for bleeding using published risk scores; (2) it allows them to interactively compare OACs to select one or more therapies that best matches their risk profile and individual preferences ; and (3) it summarizes the risk information and their selected therapy to facilitate discussion with their physician in a Summary Report. This study represents the next step in this program of research, by performing a formal evaluation of the performance of this tool in a real-world clinical setting.

Primary Objective:

To conduct a pilot study to establish the acceptability of the RAPID AFib tool and its impact on the process of shared decision-making for stroke prevention therapy in patients with recent onset AF

Hypothesis:

The RAPID Afib decision aid will be acceptable for both patients and clinicians, and will lead to more effective shared decision-making than standard care among patients with AF who are considering OAC.

Methods:

Study Design: Prospective, randomized pilot study.

Study procedures:

Clinic staff will screen referred patients, then the research team will approach them to confirm eligibility, request informed consent for participation, and collect baseline demographic and clinical data. Consenting patients will be randomized 1:1 using a web-based application linked to the study database to receive the study intervention or control. Randomization will be stratified by clinic site.

All patients will be invited to review an evidence-based website providing information about AF and its management.

Intervention group: Patients randomized to the RAPID AFib intervention will be sent a link to the decision aid website and asked to complete the decision aid before their upcoming visit. They will also be asked to bring the Summary Report to their upcoming clinic visit. A copy of the Summary Report will be added to the patient chart for clinician review.

Control group: Patients randomized to the control group will attend their clinic visit as scheduled, with no further direction from the study team.

Follow-up: Study participation will end after completion of a post-visit survey.

Conditions

Atrial Fibrillation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Patient Decision Aid

Receives web-based information and access to patient decision aid before clinic visit

Group Type: EXPERIMENTAL

Electronic patient decision aid

Intervention Type: BEHAVIORAL

Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments

Control

Receives web-based information only before clinic visit

Group Type: ACTIVE_COMPARATOR

Information

Intervention Type: OTHER

Link to website with information about atrial fibrillation treatments

Interventions

Electronic patient decision aid

Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments

Intervention Type: BEHAVIORAL

Information

Link to website with information about atrial fibrillation treatments

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Non-valvular AF diagnosed within 12 months, with any level of stroke risk assessed by CHA2DS2-VASc score.
• Age 18 or older
• Either no OAC treatment or treated for less than 90 days.
• Initial specialist AF visit scheduled in 7-30 days.

Exclusion Criteria

• Valvular AF, defined, per Canadian Cardiovascular Society Guidelines, as AF in the presence of mechanical heart valves, rheumatic mitral stenosis, or moderate to severe nonrheumatic mitral stenosis.
• Currently prescribed dual antiplatelet therapy (ASA plus either clopidogrel, ticagrelor, or prasugrel) for an indication other than AF.
• Has an independent, non-AF indication for oral anticoagulation.
• Has a non-modifiable impediment to effective use of web-based tools. Examples include lack of internet access, lack of English literacy (Grade 5 level).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Servier

INDUSTRY

Sponsor Role: collaborator

University of Calgary

OTHER

Sponsor Role: lead

Responsible Party

Stephen B. Wilton

Associate Professor, Cardiac Sciences

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Stephen B Wilton, MD

Role: PRINCIPAL_INVESTIGATOR

University of Calgary

Locations

Calgary Zone, Alberta Health Services

Calgary, Alberta, Canada

Site Status: RECRUITING

Vita Diagnostics

Calgary, Alberta, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Stephen B Wilton, MD

Role: CONTACT

sbwilton@ucalgary.ca

403-210-7102

Joel Adekanye, MPH

Role: CONTACT

joel.adekanye@ucalgary.ca

Facility Contacts

Stephen Wilton, MD

Role: primary

sbwilton@ucalgary.ca

403-210-7102

Joel Adekanye, MD

Role: backup

joel.adekanye@ucalgary.ca

Lou Kolman, MD

Role: primary

louis.kolman@ahs.ca

587-393-8482

Other Identifiers

REB22-1737

Identifier Type: -

Identifier Source: org_study_id